NASDAQ, TSX: NVCN
VANCOUVER, Sept. 19, 2018 /PRNewswire/ - Neovasc, Inc.
("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral
valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina,
announced today that a Neovasc Reducer™ (the "Reducer") has now been implanted in 100 patients in Germany. The Reducer is a wire mesh implanted into a vein in the heart which treats patients with refractory
angina.
A growing number of patients suffer from significant angina despite optimal medication and prior revascularisations (via
percutaneous coronary intervention or coronary artery bypass graft), or when revascularization is not feasible or when the risks
is too great. Refractory angina can lead to significant disability, limited quality of life, multiple medications and frequent
hospital admissions.
"This important milestone in Germany was reached earlier than originally anticipated, thanks
in large part to the Reducer being awarded NUB-status 1 earlier this year. With awareness of the Reducer therapy continuing to
build among cardiologists, we are well on our way to tripling the number of implants in Germany
for 2018 as compared to last year," stated Fred Colen, President and Chief Executive Officer of
Neovasc.
Dr. Steffen Schnupp, Klinikum Coburg, Germany, commented "We
see a growing number of patients presenting with refractory angina, despite optimal medical treatment and revascularization
therapies. The Reducer therapy is a welcome option for these patients in my center."
Dr. Schnupp and his colleague, Dr. Ashraf Salem, implanted the 100th Reducer in Coburg,
Germany. The procedure was uneventful and lasted less than 30 minutes.
"We have treated over 25 patients with the Reducer and observe a high success rate. Ninety percent of our patients have
reported a relief of symptoms and an improved quality of life," said Dr. Salem.
About Reducer
The Reducer is CE-marked in the European Union for the treatment of refractory angina, a painful and debilitating
condition that occurs when the coronary arteries deliver an inadequate supply of blood to the heart muscle, despite treatment
with standard revascularization or cardiac drug therapies. It affects millions of patients worldwide, who typically lead
severely restricted lives as a result of their disabling symptoms, and its incidence is growing. The Reducer provides
relief of angina symptoms by altering blood flow in the heart's circulatory system, thereby increasing the perfusion of
oxygenated blood to ischemic areas of the heart muscle. Placement of the Reducer is performed using a minimally invasive
transvenous procedure that is similar to implanting a coronary stent and is usually completed in approximately 20 minutes.
About Neovasc Inc.
Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing
cardiovascular marketplace. Its products include the Reducer, for the treatment of refractory angina, which is not currently
commercially available in the United States and has been commercially available in Europe since 2015, and the Tiara™ (the "Tiara"), for the transcatheter treatment of mitral valve disease,
which is currently under clinical investigation in the United States , Canada and Europe . For more information, visit: www.neovasc.com.
This news release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act
of 1995 and applicable Canadian securities laws regarding the tripling of the number of Reducer implants in Germany for 2018 as compared to last year, the growing incidence of refactory angina and the rapidly growing
cardiovascular marketplace. Words and phrases such as "expected" and "will", and similar words or expressions, are intended to
identify these forward-looking statements. Forward-looking statements are based on estimates and assumptions made by the Company
in light of its experience and its perception of historical trends, current conditions and expected future developments, as well
as other factors that the Company believes are appropriate in the circumstances. Many factors and assumptions could cause the
Company's actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking
statements, including, without limitation, the substantial doubt about the Company's ability to continue as a going concern;
risks relating to the warrants (the "Warrants") and senior secured convertible notes (the "Notes") issued pursuant to the
November 2017 underwritten public offering and concurrent private placement (together, the "2017
Financings"), resulting in significant dilution to the Company's shareholders; risks relating to the Company's need for
significant additional future capital and the Company's ability to raise additional funding; risks relating to cashless exercise
and adjustment provisions in the Warrants and Notes issued pursuant to the 2017 Financings, which could make it more difficult
and expensive for the Company to raise additional capital in the future and result in further dilution to investors; risks
relating to the sale of a significant number of Common Shares; risks relating to the exercise of Warrants or conversion of Notes
issued pursuant to the 2017 Financings, which may encourage short sales by third parties; risks relating to the possibility that
the Common Shares may be delisted from the Nasdaq Capital Market or the Toronto Stock Exchange, which could affect their market
price and liquidity; risks relating to the Company's common share price being volatile; risks relating to the influence of
significant shareholders of the Company over the Company's business operations and share price; risks relating to the Company's
significant indebtedness, and its effect on the Company's financial condition; risks relating to claims by third parties alleging
infringement of their intellectual property rights; risks relating to lawsuits that the Company is subject to, which could divert
the Company's resources and result in the payment of significant damages and other remedies; the Company's ability to establish,
maintain and defend intellectual property rights in the Company's products; risks relating to results from clinical trials of the
Company's products, which may be unfavorable or perceived as unfavorable; the Company's history of losses and significant
accumulated deficit; risks associated with product liability claims, insurance and recalls; risks relating to use of the
Company's products in unapproved circumstances, which could expose the Company to liabilities; risks relating to competition in
the medical device industry, including the risk that one or more of the Company's competitors may develop more effective or more
affordable products; risks relating to the Company's ability to achieve or maintain expected levels of market acceptance for the
Company's products, as well as the Company's ability to successfully build its in-house sales capabilities or secure third-party
marketing or distribution partners; the Company's ability to convince public payors and hospitals to include the Company's
products on their approved products lists; risks relating to new legislation, new regulatory requirements and the efforts of
governmental and third-party payors to contain or reduce the costs of healthcare; risks relating to increased regulation,
enforcement and inspections of participants in the medical device industry, including frequent government investigations into
marketing and other business practices; risks associated with the extensive regulation of the Company's products and trials by
governmental authorities, as well as the cost and time delays associated therewith; risks associated with post-market regulation
of the Company's products; health and safety risks associated with the Company's products and industry; risks associated with the
Company's manufacturing operations, including the regulation of the Company's manufacturing processes by governmental authorities
and the availability of two critical components of the Reducer; risk of animal disease associated with the use of the Company's
products; risks relating to the manufacturing capacity of third-party manufacturers for the Company's products, including risks
of supply interruptions impacting the Company's ability to manufacture its own products; risks relating to the Company's
dependence on limited products for substantially all of the Company's current revenues; risks relating to the Company's exposure
to adverse movements in foreign currency exchange rates; risks relating to the possibility that the Company could lose its
foreign private issuer status under U.S. federal securities laws; risks relating to breaches of anti-bribery laws by the
Company's employees or agents; risks associated with future changes in financial accounting standards and new accounting
pronouncements; risks relating to the Company's dependence upon key personnel to achieve its business objectives; the Company's
ability to maintain strong relationships with physicians; risks relating to the sufficiency of the Company's management systems
and resources in periods of significant growth; risks associated with consolidation in the health care industry, including the
downward pressure on product pricing and the growing need to be selected by larger customers in order to make sales to their
members or participants; risks relating to the Company's ability to successfully identify and complete corporate transactions on
favorable terms or achieve anticipated synergies relating to any acquisitions or alliances; risks relating to the Company's
ability to successfully enter into fundamental transactions as defined in the Series C warrants issued pursuant to the 2017
Financings; anti-takeover provisions in the Company's constating documents which could discourage a third party from making a
takeover bid beneficial to the Company's shareholders; and risks relating to conflicts of interests among the Company's officers
and directors as a result of their involvement with other issuers. These risk factors and others relating to the Company are
discussed in greater detail in the "Risk Factors" section of the Company's Annual Report on Form 20-F and in Management's
Discussion and Analysis for the quarter ended June 30, 2018 (copies of which may be obtained at
www.sedar.com or www.sec.gov). The Company has no intention and undertakes no obligation to update or revise any
forward-looking statements beyond required periodic filings with securities regulators, whether as a result of new information,
future events or otherwise, except as required by law.
View original content:http://www.prnewswire.com/news-releases/neovasc-announces-100th-patient-to-receive-reducer-therapy-in-germany-300715404.html
SOURCE Neovasc Inc.